Health Canada Authorizes Etiometry’s IDO2 Index™ for Adult Use

Healthcare providers across Canada can now implement the IDO2 Index for adult patients in the ICU, which provides a risk estimation of inadequate oxygen delivery

June 06, 2022 08:00 AM Eastern Daylight Time

BOSTON–(BUSINESS WIRE)–Etiometry, a leader in clinical decision-support software for critical care, today announced the first market authorization of the company’s IDO2 Index for use in adult patients. With the Health Canada authorization, Etiometry may immediately begin expanding sales and implementations of the IDO2 Index, which trends the risk of inadequate oxygen delivery, in intensive care settings across Canada. This authorization marks Etiometry’s second Health Canada authorization in addition to the six FDA clearances for the Etiometry software platform.

The IDO2 Index was first introduced in 2016 and developed to be utilized initially for pediatric intensive care patients and has now expanded to meet the needs of adult intensive care patients. The IDO2 Index uses advanced algorithms to interpret multiple sources of patient data and provides the care team with a visualization of the patient-specific risk estimation capable of making providers aware of potential patient deterioration. Heightened awareness can facilitate timely intervention, optimized clinical workflows, and improved outcomes.

Etiometry’s success has been driven through utilization and adoption of the Etiometry software platform’s ability to create a holistic view of the patient that empowers rapid, informed decision-making, due in no small part to the IDO2 Index. The Canadian authorization of the IDO2 Index into the adult market signifies Etiometry’s expansion into all patient demographics providing the opportunity to assist more facilities in providing the best possible care for their patients.

“The Health Canada approval of our IDO2 Index for adults represents an important milestone as our company adds this to our roster of both Health Canada and FDA cleared offerings,” said Shane Cooke, CEO of Etiometry. “Now, health systems in Canada will be able to implement near-real-time adequate oxygen delivery estimation of their patients, which they can use to help avoid complications related to hypoxic conditions and decrease ICU length of stay.”

Etiometry’s software platform provides a comprehensive solution to streamline management and decision-making for critically ill patients, yielding better outcomes and significant economic savings. The platform aggregates disparate patient data from patient monitors and other clinical systems, displaying remotely or at the bedside in one consolidated view. The proprietary risk analytics provide trending of physiological conditions to manage dynamic patient care needs. The platform’s Quality Improvement System provides a normalized database of all collected data, and automated reporting that supports quality improvement and clinical research. Etiometry partners with more than 35 hospitals, including more than 20 of the top children’s hospitals in the United States, as ranked by U.S. News & World Report, and a growing list of top adult academic medical centers.

About Etiometry
Founded in 2010, Etiometry is a leader in clinical decision-support software designed to help clinicians in the intensive care setting make data-based decisions regarding their patients’ care and treatment. The company’s technologies provide valuable clinical insight and analysis to support early recognition of subtle changes in patients’ conditions to avoid complications and speed recovery. With roots in pediatric ICUs, Etiometry’s software is utilized in more than 20 of the top U.S. children’s hospitals and a growing number of top adult hospitals. Etiometry is committed to improving patient outcomes, increasing clinical efficiency, and lowering the cost of care through the more effective use of data. To learn more, visit www.etiometry.com.